Systemic Carnitine Deficiency

Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in mental health and addiction care Vancouver, Canada, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its pioneering combination therapy of Ibogaine and N-Acylethanolamines. Ibogaine, a key compound derived from the root of Tabernanthe iboga, a shrub native to West and Central Africa, has shown promise in human clinical trials for treating opioid use disorder (OUD), cocaine use disorder (CUD), and other substance use disorders (SUD). As a result, Ibogaine is considered a potentially effective anti-addiction agent. The patent application follows innovative developments from Clearmind’s successful collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA). Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: “The publication of this patent highlights Clearmind’s commitment to leadership in the psychedelics space through building a diverse patent portfolio, featuring technologies with varying timelines to market. Most importantly, we aim to provide safe and effective solutions for mental health conditions that currently have unmet needs. While treatments with Ibogaine are generally considered safe under proper medical supervision, there have been reports of fatalities or adverse events associated with the ingestion of iboga plant material or Ibogaine. We believe that combining Ibogaine with Palmitoylethanolamide will further enhance the efficacy and safety of this promising therapy.” About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.” About SciSparc Ltd. SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace. For further information visit: https://www.clearmindmedicine.com or contact: Investor Relationsinvest@clearmindmedicine.com Telephone: (604) 260-1566US: CMND@crescendo-ir.com General Inquiries Info@Clearmindmedicine.com www.Clearmindmedicine.com Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses Clearmind’s commitment to be a leader in the psychedelics space by creating a diverse patent portfolio, which contains various technologies with different times to market, but more importantly provides efficacious and safe solutions to various mental health conditions with unmet needs. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

THURSDAY, Sept. 5, 2024 -- The stereotype of the slacker stoner might not be too far off the mark, a new study shows. People who use weed are prone to workplace absenteeism -- and the more problematic the cannabis use, the more likely they are to skip work, results showed. “These findings underscore the importance of developing and implementing strategies to monitor, screen and intervene with individuals at risk for problematic cannabis use,” concluded the research team led by Dr. Kevin Yang , a psychiatric resident with the University of California, San Diego. “To address these issues, workplace prevention programs focusing on education, screening and access to treatment are imperative,” the team said in the paper, which was published recently in the American Journal of Preventive Medicine. For the study, researchers analyzed data on nearly 46,500 people gathered in 2021 and 2022 as part of the National Survey on Drug Use. Nearly 16% of full-time employed adults in the survey said they’d used weed in the past month, and almost 7% appeared to have cannabis use disorder, researchers found. People were more likely to skip work if they’d used weed in the past moth, results showed. Those who used the drug once or twice were 57% more likely to skip work than non-users, while those who used 20 to 30 days were 83% more likely to shrug off their work responsibilities, researchers found. Weed use also was associated with an increased likelihood someone would miss work due to injury or illness. Further, a person’s level of cannabis use disorder directly impacted how often they skipped work, researchers found. Workers with the most severe cannabis use disorder (CUD) were 2.8 times as likely to miss work as people who never use weed. By comparison, those with moderate CUD were twice as likely to skip work, and those with mild use disorder were 60% more likely to miss work. Marijuana can cause reduced motivation and other brain changes, which might explain why tokers are more likely to skip work, the researchers said. “With regard to skipping work, common stereotypes suggest that cannabis makes users ‘lazy,’ and there is research supporting that cannabis consumption can lead to reduced motivation and cognitive changes,” the researchers wrote. “This phenomenon may partially explain why individuals with cannabis use and CUD are more likely to skip work.” Cannabis use also has been linked to factors that can contribute to increased absenteeism, like anxiety, panic attacks, depression, sleep disturbances, respiratory problems and vehicle accidents, the researchers wrote. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Aelis Farma is reviewing the results of its phase 2b cannabis use disorder study and is yet to decide on the next steps. Aelis Farma’s hopes of securing a quick, positive decision on a $100 million option payment have gone up in smoke. The French biotech reported the failure of its phase 2b cannabis use disorder (CUD) study Wednesday, prompting its partner Indivior to say it doesn’t currently expect to exercise its option.Indivior paid $30 million for an option to license the candidate in 2021. The British drugmaker planned to make a decision on AEF0117, a signaling-specific inhibitor of cannabinoid receptor 1 (CB1), after seeing the phase 2b data and hearing what the FDA has to say on clinical endpoints for future studies. However, the failure of the study prompted Indivior to signal its intentions without waiting for the FDA’s feedback.The prompt dampening of expectations about the likelihood of a deal followed an analysis of clinical data that paints a bleak picture of the prospects of AEF0117. Aelis randomized 333 treatment-seeking people with moderate to severe CUD to receive one of three doses of AEF0117 or placebo for 12 weeks.Participants used cannabis at least five days a week at baseline. AEF0117 was no better than placebo at reducing use to one day a week, causing the study to miss its primary endpoint. The study also missed secondary endpoints that looked at the proportion of patients who completely abstained or cut their use to two days a week. Aelis is yet to share the numbers behind the failures but did note “a very low placebo effect for these endpoints.” With AEF0117 failing to beat placebo, the comment suggests there was little improvement on the endpoints in the treatment arms. The data are a blow to the hypothesis that selectively blocking CB1 can decrease cannabis use by inhibiting signaling pathways that drive its intoxicating effects.The only positives disclosed by Aelis related to safety and tolerability, which was similar in the treatment and placebo groups, and the effect of the highest dose on some secondary endpoints. Aelis reported “consistent positive trends” on quantitative endpoints measuring the total amount of cannabis used and “a nearly statistically significant effect” on measures of anxiety, depression and sleep quality.Some of the decreases in quantitative measures of cannabis use were statistically significant in people with moderate CUD. The moderate CUD subgroup was small, though, with 82% of participants having the severe form of the disorder.Aelis is still reviewing the results and is yet to decide on the next steps. Indivior doesn’t intend to take up its option, although it is yet to conclusively abandon the deal, and favorable clinical data could shift its thinking.